Onkologie. 2011:5(3):163-168 [Interní Med. 2011; 13(6): 266-271]

Diabetes and malignant tumour

Petra Tesařová
Onkologická klinika 1. LF UK a VFN, Praha

In addition to having specific effects in terms of glucose metabolism, the insulin-like growth factor type 1 (IGF-1) and insulin also possess

a mitogenic effect that, by means of IGF1 receptors (IGF1-R) and insulin receptors (IR) often present on tumour cells, may be exerted by

potentiation of tumour growth. The close link between carcinogenesis and glucose metabolism then results in interference of both these

processes by drugs used to treat either condition. An understanding of the molecular mechanisms mediated by both receptors allows

the clinician to predict adverse effects of treatment as well as to control the oncological safety of diabetes treatment.

Keywords: diabetes, malignant tumour, insulin, insulin receptor, IGF1, IGF1-R

Published: July 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tesařová P. Diabetes and malignant tumour. Onkologie. 2011;5(3):163-168.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Simon D, Balkau B. Diabetes mellitus, hyperglycaemia and cancer. Diabetes Metab. 2010; 36(3): 182-191. Go to original source... Go to PubMed...
    2. Nicolucci A. Epidemiological aspects of neoplasms in diabetes. Acta Diabetol. 2010; 47(2): 87-95. Go to original source... Go to PubMed...
    3. Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol. 2011; 29(1): 40-46. Go to original source... Go to PubMed...
    4. Hursting SD, Berger NA. Energy balance, host-related factors, and cancer progression. J Clin Oncol. 2010; 28(26): 4058-4065. Go to original source... Go to PubMed...
    5. Meyerhardt JA, Ma J, Courneya KS. Energetics in colorectal and prostate cancer. J Clin Oncol. 2010; 28(26): 4066-4073. Go to original source... Go to PubMed...
    6. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocrine-related cancer 2009; 16: 1103-1123. Go to original source... Go to PubMed...
    7. Irwin ML, Duggan C, Wang CY, et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol. 2011; 29(1): 47-53. Go to original source... Go to PubMed...
    8. DeCensi A, Gennari A. Insulin breast cancer connection: confirmatory data set the stage for better care. J Clin Oncol. 2011; 29(1): 7-10. Go to original source... Go to PubMed...
    9. Duggan C, Irwin ML, Xiao L, et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol. 2011; 29(1): 32-39. Go to original source... Go to PubMed...
    10. Platts J. Insulin therapy and cancer risk in diabetes mellitus. Clin Med. 2010; 10(5): 509-512. Go to original source... Go to PubMed...
    11. Call R, Griemsley M, Cadwallader L, et al. Insulin - karcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic and colorectal research. Postgraduate medicine 2010; 122(3): 158-165. Go to original source... Go to PubMed...
    12. McFarland MS, Cripps R. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs. Pharmacotherapy 2010; 30(11): 1159-1178. Go to original source... Go to PubMed...
    13. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res. 2010; (11): 1451-1461. Go to original source... Go to PubMed...
    14. Dziadziuszko R, Merrick DT, Witta SE, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol. 2010; 28(13): 2174-2180. Epub 2010 Mar 29. Go to original source... Go to PubMed...
    15. Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab. 2010; 21(10): 610-618. Go to original source... Go to PubMed...
    16. Tsugane S, Inoue M. Insulin resistance and cancer: epidemiological evidence. Cancer Sci 2010; 101(5): 1073-1079. Go to original source... Go to PubMed...
    17. Danne T, Bolinder J. New insulins and the risk of cancer. Int J Clin Pract Suppl. 2010; (166): 26-28. Go to original source... Go to PubMed...
    18. Herrera BM, Lindgren CM. The genetics of obesity. Curr Diab Rep. 2010; 10(6): 498-505. Go to original source... Go to PubMed...
    19. Stefansdottir G, Zoungas S, Chalmers J, et al. Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia 2011 (e-pub). Go to original source...
    20. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010; 49(11): 1603-1616. Go to original source... Go to PubMed...
    21. Pitocco D, Zaccardi F, Di Stasio E, et al. Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud. 2010; 7(1): 15-25. Go to original source... Go to PubMed...
    22. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, et al. If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials. J Clin Oncol. 2009; 27(33): e207-209. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.